Mar Nataliya, Kosowicz Rebecca, Hook Karen
Department of Hematology/Oncology, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT, 06030, USA,
J Thromb Thrombolysis. 2014;38(2):196-200. doi: 10.1007/s11239-014-1061-x.
We report a case of a 36-year old patient with prior history of thrombosis in a setting of antiphospholipid antibody syndrome (APS) as well as pregnancy-associated catastrophic antiphospholipid syndrome (CAPS), resulting in multi-organ infarction and pregnancy loss. The episode of CAPS occurred while she was receiving antepartum low-dose aspirin and therapeutic-dose enoxaparin. This patient presented again at 6 weeks gestation and ultrasounds were consistent with fetal growth restriction, concerning for placental insufficiency and thrombosis. This time, hydroxychloroquine and monthly intravenous immunoglobulin (IVIG) infusions were added to her prophylaxis regimen, resulting in a successful delivery. Platelet count and antiphospholipid antibody titers were routinely monitored throughout pregnancy as markers of disease activity for APS. Current thromboprophylaxis guidelines do not address therapeutic options to prevent further pregnancy morbidity in women who develop recurrent episodes of thrombosis or CAPS despite receiving adequate anti-thrombotic treatment. Use of hydroxychloroquine and IVIG has been associated with good outcomes in this subset of patients.
我们报告了一例36岁患者,其既往有抗磷脂抗体综合征(APS)背景下的血栓形成病史,以及妊娠相关的灾难性抗磷脂综合征(CAPS),导致多器官梗死和妊娠丢失。CAPS发作时她正在接受产前低剂量阿司匹林和治疗剂量的依诺肝素。该患者在妊娠6周时再次就诊,超声检查结果与胎儿生长受限一致,提示胎盘功能不全和血栓形成。此次,在她的预防方案中加入了羟氯喹和每月一次的静脉注射免疫球蛋白(IVIG),最终成功分娩。在整个孕期常规监测血小板计数和抗磷脂抗体滴度,作为APS疾病活动的标志物。目前的血栓预防指南未涉及尽管接受了充分的抗血栓治疗但仍发生复发性血栓形成或CAPS发作的女性预防进一步妊娠并发症的治疗选择。在这部分患者中,使用羟氯喹和IVIG已取得了良好的效果。